Efficiency of prostacyclin in the treatment of protamine-mediated right ventricular failure and acute pulmonary hypertension.
暂无分享,去创建一个
[1] O. Goksel,et al. Carotid-subclavian bypass in occlusive disease of subclavian artery: more important today than before. , 2004, The Tohoku journal of experimental medicine.
[2] G. Dehmer,et al. Recombinant platelet factor 4 for heparin neutralization. , 2004, Seminars in thrombosis and hemostasis.
[3] P. Evora,et al. Catastrophic cardiovascular adverse reactions to protamine are nitric oxide/cyclic guanosine monophosphate dependent and endothelium mediated: should methylene blue be the treatment of choice? , 2002, Chest.
[4] G. Gravlee,et al. A Dose-Determining Trial of Heparinase-I (Neutralase™) for Heparin Neutralization in Coronary Artery Surgery , 2001, Anesthesia and analgesia.
[5] M. Kikura,et al. Heparinase I (Neutralase) Reversal of Systemic Anticoagulation , 1996, Anesthesiology.
[6] H. Schaff,et al. Protamine induces endothelium-dependent vasodilatation of the pulmonary artery. , 1995, The Annals of thoracic surgery.
[7] J. Levy,et al. Heparin Neutralization by Recombinant Platelet Factor 4 and Protamine , 1995, Anesthesia and analgesia.
[8] M. Fisher,et al. Reversal of heparin anticoagulation by recombinant platelet factor 4 in humans. , 1995, Circulation.
[9] L. Edmunds,et al. Reversal of heparin anticoagulation by recombinant platelet factor 4 and protamine sulfate in baboons during cardiopulmonary bypass. , 1995, The Journal of thoracic and cardiovascular surgery.
[10] S. W. Kim,et al. Heparin removal from blood using poly(L‐lysine) immobilized hollow fiber , 1992, Biotechnology and bioengineering.
[11] H. Schaff,et al. Protamine Releases Endothelium‐Derived Relaxing Factor From Systemic Arteries: A Possible Mechanism of Hypotension During Heparin Neutralization , 1992, Circulation.
[12] D. Mosser,et al. Platelet Factor 4 Efficiently Reverses Heparin Anticoagulation in the Rat Without Adverse Effects of Heparin–Protamine Complexes , 1992, Circulation.
[13] J. Wain,et al. Inhaled nitric oxide. A selective pulmonary vasodilator of heparin-protamine vasoconstriction in sheep. , 1991, Anesthesiology.
[14] K. Peter,et al. [Complications caused by protamine. 1: Pharmacology and pathophysiology]. , 1991, Der Anaesthesist.
[15] W. Weintraub,et al. Evaluation of patients at risk for protamine reactions. , 1989, The Journal of thoracic and cardiovascular surgery.
[16] S. Thomas,et al. C5a and thromboxane generation associated with pulmonary vaso- and broncho-constriction during protamine reversal of heparin. , 1987, Anesthesiology.
[17] T. Quattrociocchi-Longe,et al. Interrelationship of protamine and platelet factor 4 in the neutralization of heparin. , 1987, Thrombosis research.
[18] J. Zaidan,et al. Prospective Evaluation of Risk of Protamine Reactions in Patients with NPH Insulin‐Dependent Diabetes , 1986, Anesthesia and analgesia.
[19] T. Ryan,et al. Increased risk of severe protamine reactions in NPH insulin-dependent diabetics undergoing cardiac catheterization. , 1984, Circulation.
[20] B. Milne,et al. The haemodynamic effects of intraaortic versus intravenous administration of protamine for reversal of heparin in man , 1983, Canadian Anaesthetists' Society journal.
[21] H. Schaff,et al. Cardiovascular effects of protamine sulfate in man. , 1982, The Journal of thoracic and cardiovascular surgery.
[22] R. Frater,et al. CARDIOVASCULAR EFFECTS OF RIGHT ATRIAL INJECTION OF PROTAMINE SULFATE AS COMPARED TO LEFT ATRIAL INJECTION , 1982 .
[23] M. K. Sykes,et al. Effects of heparin and protamine on left ventricular performance in the dog. , 1979, Cardiovascular research.